Myanamar to relax drug-making rules

3 September 2006

The government of Myanamar (formerly Burma) is considering the possibility of allowing the country's private sector to start manufacturing pharmaceuticals, following a meeting at the Ministry of Industry in Nay Pyi Taw. Currently, the government does not allow the private sector to produce cigarettes, beer or pharmaceuticals.

Pharmaceuticals produced domestically are manufactured solely by the Myanmar Pharmaceutical Industry at three factories, one in Yangon and two in the Mandalay Division and, according to official statistics, the three factories produce 40% of pharmaceuticals sold on the local market. The remainder are imported mainly from Bangladesh, India, China and Thailand. In an interview, U Myat Thin Aung president of the Myanmar Industrial Association, said: "whilst most pharmaceuticals legally imported are safe, most imported via border-trade cannot be trusted, and some are fake drugs that have not been approved by the Food and Drugs Administration. The production of pharmaceuticals by the private sector would thus reduce cross-border imports of these dangerous drugs."

Maung Mang Lay, president of the Myanmar Pharmaceuticals and Medical Equipment Entrepreneurs Association, said the body welcomes initiatives from other countries to bring more medicines into Myanmar because it increases consumer choice.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight